Due to its longer half-life comparing to glucagon-like peptide 1 (GLP), the endogenous ligand of GLP-1R, exendien-4 has better and longer-lasting effects on promoting glucose-dependent insulin secretion [1, 3, 4, 5, 6]
5-Amino-1MQ has shown potential in enhancing energy, promoting healthy aging, and boosting fat metabolism, all in a clinically safe and cost-effective way
doi:10.1007/s12017-012-8184-z 136
Weight loss continues throughout the 68-week treatment period with many participants still showing downward trajectories, suggesting further weight loss might be possible with continued treatment
And that's kind of true for type 1 diabetes, which is maybe 5% of all cases